The programme was divided into several distinct categories: an analysis of the problem and experience of ovarian cancer management from several centres including surgical staging and cytoreduction, the place of second-look laparotomy and the successes and limitations of chemotherapy and alternative forms of management. Ovarian cancer pathology was reviewed for both epithelial and germ cell tumours and prognostic factors discussed. Laboratory models for ovarian cancer included tumour culture and drug sensitivity evaluation, the influence of fe&der cells and the analysis of resistance and the use of the nude mouse as a model for monoclonal antibody therapy. Tumour 
The programme was divided into several distinct categories: an analysis of the problem and experience of ovarian cancer management from several centres including surgical staging and cytoreduction, the place of second-look laparotomy and the successes and limitations of chemotherapy and alternative forms of management. Ovarian cancer pathology was reviewed for both epithelial and germ cell tumours and prognostic factors discussed. Laboratory models for ovarian cancer included tumour culture and drug sensitivity evaluation, the influence of fe&der cells and the analysis of resistance and the use of the nude mouse as a model for monoclonal antibody therapy. Tumour markers were reviewed, their detection with antibodies and clinical usefulness then discussed. Other laboratory studies included investigation of receptor status, expression of MHC products, the development of monoclonal antibodies and investigation of drug concentrations surrounding tumour cells in vivo.
C.N. Hudson reviewed the extent of the problem in ovarian cancer management and presentation by reference to a North West Thames prospective study of > 1,000 patients: the natural history and therapeutic practice between 1973 and 1980 . He pointed out that most patients received diagnosis and follow-up with general gynaecologists with no interest in malignancy and whose experience will be limited.
Within the study, the histology was unremarkable, although the incidence of endometrioid cancer was high, that of metastatic disease lower than anticipated, but age was found to be an important variable with a bias in favour of stage and grade found in younger cohorts. Few patients presented with menstrual disturbance or postmenopausal bleeding, abdominal swelling, abnormal or inappropriate hormone production or pleural effusions. Neurological, vascular or cutaneous features were rare, but there was a disproportionate incidence of indigestion as a factor in early disease. There was also a clear distinction between early and late progression of disease, the former attributed both to unrecognised understaging and to conservative surgery to conserve reproductive function. Less than 50% patients with advanced disease had sub-total hysterectomy, indicating far from maximal cytoreduction, and the total 14% survival was far worse than that from recognised therapeutic centres, indicating a lack of understanding as to what might be achieved by effective surgery and followup. It was stated that maximal cytoreduction should be achievable in the majority of Stage III patients and, until it was understood that ovarian carcinoma was only inoperable in the upper abdomen and then infrequently so, patients were unlikely to obtain benefit from other advances in treatment. Raising awareness of this amongst clinicians and medical undergraduates was therefore a priority. Questioned by J. Berlie about a control study to assess epidemiology, he confirmed that this was done for 200 patients and in answer to F. Lawton stated that gynaecologists had learnt little in terms of changing surgical practice over the period of study. R.C. Knapp commented that tumour biology might influence the surgeon's ability to perform cytoreductive surgery and A. Govan confirmed that some tumours stimulate dense fibrous tissue growth. B. Ward added that there was a relationship between diploid tumours and operability. In answer to A. Talerman and J. Baak, Prof. Hudson confirmed that the tumours studied were graded according to the worst area found and that all were studied by the Regional Pathologist.
Complementary to this, M. Kaufmann presented a study from Heidelberg involving a 25 year review of 370 epithelial ovarian carcinomas. There was clear evidence that low stages are becoming rarer and that Stages III and IV are on the increase. Survival by stage followed the usual trend but the advent of cis-platinum, together with more aggressive surgery, has had a marked influence on survival. For Stage IV patients, where the younger cohorts fared worse there was no difference in outcome between chemotherapy alone or combined with radiotherapy whereas aggressive chemotherapy, followed by radiotherapy, has had a marked influence on Stage III survival. Of 87 patients, III and IV, 41 had second-look laparotomy and 18% had no microscopic disease. Five year survivals were now 33% compared to 15% for less aggressive management. It was clear that this improvement was due both to more accurate staging procedures and to risk-adapted aggressive therapy. B.
Ward asked about the malignant potential of the tumours studied and A. Simmonds submitted that in her experience, behaviour of primary tumours in culture had not yet been correlated with stage of disease, prognosis or tumour aggression. There followed a vigorous discussion about the benefit of second-look procedures with B.-U. Sevin commenting that he had cured Stage IV patients with aggressive surgery by looking for tumour while K.K. Chan doubted the benefits of such follow-up, citing similar survivals in NED and residual microscopic disease patients. I. Rocker commented that although we must have the knowledge derived from 'second-look', many surgeons will refuse to do it.
The place of surgery in the treatment of ovarian cancer was presented by B.-U. Sevin with the controversial aspects being reviewed by K.K. Chan. The former outlined the functions of surgery as diagnosis, correct surgical staging and debulking. The surgeon must look for tumour until it is found and the residual tumour volume must be reduced to a minimum. Since tumour nodules larger than 0.5 cm may not receive drug due to poor penetration and since the presence of hypoxic areas makes radiotherapy insufficient or ineffective, it is clear that primary surgery has the greatest influence on prognosis. Gross tumour must be removed without rupture, washings taken and any remaining masses defined and recorded diagrammatically. The retroperitoneal space and the pelvic and para aortic lymph nodes must also be investigated. A typical debulking laparotomy was described starting with a mid-line incision. A valid assessment of macro and microscopic disease must be made by examining the upper abdomen using a light, by palpation and by washing. A radical oophorectomy and retroperitoneal resection should be performed and Dr Sevin outlined the use of a variety of automated stapling equipment which can cut, ligate and staple and which is particularly valuable in sub-total omentectomy and resection of bowel/colon as part of debulking. Some patients might additionally benefit from resection of the rectosigmoid. The value of radical surgery was again stressed by figures indicating that those patients (20%) with microscopic disease at 'second-look' had 96% 2 year and 71% 5 year survivals irrespective of therapy. Those patients with negative second-look had 85% 5 year survival. Patients with less than 0.5cm residual disease had whole abdomen irradiation and may also have i. Antigens found to date have a wide spectrum of distribution e.g. MH99 being characteristic of all epithelial cells regardless of origin and MH941 restricted to secretory epithelia is unreactive with normal ovarian epithelia, but stains epithelia surrounding ovarian cysts and many ovarian carcinomas. MT 334 reacts only with colonic crypt cells among normal tissues examined but is found on a proportion of cell lines and other epithelial tumours of lung. Ovarian tumours are invariably positive, benign as well as malignant, while less than 10% of sera from ovarian cancer patients had elevated levels. The secreted antigen 116 is found exclusively in culture medium and is impossible to detect on the cell surface, but appears to be confined to ovarian tumours. The Y antigen is an example of the blood group antigens differentially expressed on epithelia of different kinds and its expression is therefore related both to the patient blood type and secretor status. Conclusions from this study are that antigens restricted to tumours are rare, but that the use of antibodies in imaging and radiolocalisation has been achieved with CEA and milk fat globule protein and work in progress is exploring the use of lectin, drug and isotope conjugates.
R. Knapp commented that panels of antibodies would be necessary in any likely therapy, as there can be change or loss of antigens as metastases develop. In answer to A. Talerman concerning the frequency of antigen expression in metastases, Dr Lloyd said that it had only been studied in blood group antigens where metastases and most malignancies do express them although such expression might be lost progressively.
R. Knapp opened a long session on CA125 antigen by reviewing its distribution and properties and making a clinical evaluation of the CA125 immunoradiometric assay. He stressed that, although 'normal' tissues are negative, benign, borderline and malignant tumours may be positive, therefore the antigen is not specific to ovarian cancer. Using the two cut-off points of 35 and 65 U ml -1, there is a spectrum of false positives in that 1% of apparently healthy subjects are positive. Levels may also be elevated in endometriosis, fibroids and pelvic inflammatory disease. It is elevated also in acute diverticulitis but not in the pneumonia subjects studied.
In a review of the use of the assay, clear areas were discussed (i) can it detect ovarian cancer in screening? (ii) whether it can be used in diagnosis (iii) whether it can do away with 'second look' by both providing evidence of residual disease and predicting clinical outcome and (iv) whether it can predict failure of therapy.
The assay cannot differentiate benign from malignant pelvic masses, but on patients with known malignant disease, assays were taken prior to surgery and up to second-look. Levels remained elevated following poor cytoreductive surgery but where surgery was maximal and they remained <35Uml-P up to second-look, this was negative. Where levels showed a gradual rise up to second-look, this was positive. Reduction of marker to < 35 U ml-I over a 3 month period was an early indicator of successful therapy. For borderline tumours CA125 levels rose in some patients 6-8 months before developing a clinical recurrence. With respect to avoiding second-look procedures, all patients with assay levels >35 U ml-had tumours even when clinically and radiologically negative; there were no false positives. However, patients may still have tumours if assay levels are less than 35 U ml-1.
As a prognostic indicator following second-look, CA125 levels increased in patients who fared badly, but a single assay at second-look was only of value for one year i.e. >35 U ml-1 signified a poor outcome and such levels occurred 3-4 months prior to clinical or radiographic recurrence. Similarly, it is suggested that second-look could be avoided if assay levels are >35 Uml-1, but it is suggested that, where patients are clinically negative but surgically positive, the assay should be done every 4 months for 2 years and those negative overall should be followed at 6 month intervals. In answer to a query about the two levels 35 and 65 U ml-1, Prof. Knapp pointed out that 65 is the limit for detection but the 35 value is more sensitive for evaluations. Mr Adams queried the effects of surgery on CA125 levels; these were elevated in patients with perforated ulcers but levels fell back. C. Selby commented that this was also true for a benign thecoma prior to surgery. C. Naylor was interested in the levels found in pregnant women; 50% of patients had elevated levels in the first two trimesters, these then fall in the third.
Contributions on the use of CA125 in different centres in the UK were made by R. Leonard The role of immunotherapy was discussed by C. Nowotony. Its aim is to restore or activate immune function, although its usefulness has not yet been established in clinical practice. A streptococcal preparation, OK432, was administered i.p. to patients with ascites, who had already become resistant to radiotherapy and chemotherapy. Doses were increased to give maximal effects and for 4/7 patients this resulted in complete disappearance of ascites and for 2/7 a reduction in ascites volume. Three patients are still alive, one 14 months post-treatment. A reduction in tumour mass was also seen, together with reduction in plating efficiency of ascitic cells. There was clear augmentation of natural killer cell activity and autologous cytotoxicity and a reduction of suppressor cell activity of the peripheral blood and exudate derived effector cells. These pronounced results had not been expected and, in answer to questions, Dr Nowotony emphasized that reduction in tumour size had been clearly seen on ultrasound but that CA125 levels remained high; the patients were not tumour free but had stable disease.
A number of laboratory studies as an aid to diagnosis and management of ovarian cancer were presented. R. Leake had evaluated oestrogen and progesterone status of 45 patients with epithelial ovarian tumours. An investigation of 105 normal ovaries had shown that 60-70% are ER and PR positive and it has been suggested that ER and PR positive patients have a better chance of survival and that it is a good prognostic indicator.
Assays were carried out on both soluble and nuclear fractions from each biopsy. Seven of 45 (16%) patients were positive for both receptors; 10/45 (22%) were positive for progesterone receptors and the situation PR+ve (ER-ve) was uncommon. Patient follow up indicated that those dying within a few months are receptor negative while those surviving 15-18 months are positive. There is therefore a clear survival advantage in receptor positive status, but the measurement of ER alone has little value. The 15% of patients in this category could receive progestin therapy; one patient who received it had a CR and has survived 15 months to date. In answer to questions, Dr Leake confirmed that the highly differentiated tumours are receptor positive, and that the problems of contrasting normal, benign and malignant tissue in the ovary can be resolved by using antibodies to detect the number of malignant epithelial cells relative to the total.
M. Moore presented a study of the expression of MHC products and leucocyte differentiation antigens in normal ovary and ovarian carcinoma. Two of the classes of MHC molecules are: I HLA-A, B, C -expressed on virtually all nucleated cells and II HLA-D, largely confined to cells of the immune system but which may also be found aberrantly on epithelia where the interest is in the possibility that they may have a role in autoimmune phenomena and in tumour cell recognition in the autocrinous host. If target cells lack Class I, they may not be recognised by cytotoxic T cells and MHC status is important in the context of conventional immunological recognition.
An immunohistological investigation of normal ovary and ovarian tumours was described using monoclonal antibodies on fresh tissue by conventional immunocytochemical techniques. Ten epithelial malignancies examined were Class I negative, but this feature is not specific to ovarian carcinoma, having been found in other tumours. Class II products were detectable in 4/8 tumours, the pattern of staining being either uniform or heterogeneous. The implication from this early study is that lack of Class I products favours the tumour at the expense of the host by removing neoplastic cells from immune recognition, but it is not yet possible to relate MHC expression to prognosis.
A further study investigating monoclonal antibodies and their possible use in detecting residual or recurrent disease was presented by F. Al-Azzawi. Lack of specificity for ovarian tumour antigens has been a problem. In an earlier study, immune complexes from pregnancy sera were found to react with ovarian cancer cells and placental trophoblast. This beta 1 PAM was used in the form of pregnancy immune complexes to produce antibodies by standard hybridoma technology. Five cell lines were obtained and characterised and two monoclonal antibodies were chosen for further study based on their strong binding to cell lines and tissue staining characteristics.
Lymphocytes have also been obtained from the drainage of lymph nodes of ovarian cancer patients and transforming them with Epstein Barr virus to produce tumour monoclonal antibody secreting lines showing specificity for ovarian cancer antigens. Fourteen have now been produced and grown for 9-21 months in continuous culture. Using fluorescein isothiocyanate, cryostat sections have been stained with labelled antibody. In the 11 specimens studied so far, binding has been observed in serous and poorly differentiated adenocarcinoma but not to mucinous and endometrioid. Clearly, human monoclonal antibodies have gross advantages over murine, although there are several problems concerning EB virus technology, in particular the low level of antibody produced and the fluctuation in antibody production. In the discussion which followed, there was concern expressed about specificity for ovary, but it was made clear that teratoma and colon specimens have also been evaluated to date.
An intraperitoneal model for radio-iodinated monoclonal antibody therapy using the nude mouse was presented by B. Ward. There is a clear role for immunoscintigraphy using i.v. monoclonal antibodies, but not more than 2% of the injected dose penetrates the tumour, creating problems for possible therapy. The human ovarian cancer cell line, JAM, established from a patient with a poorly differentiated mucinous cystadenocarcinoma forms subcutaneous and intraperitoneal tumours when injected into the nude mouse. Ascites which form can be removed from the mouse and re-established in tissue culture. All these tumour cells express the HLA-A, B, C core protein, defined by the monoclonal antibody W6/32 and expressed more strongly in the presence of human gamma interferon. An HLA Class II determinant, defined by monoclonal antibody CA2 is not expressed. These 2 antibodies were labelled with 1125 and injected into female nude mice for distribution studies. Similar results were found in tumour and non-tumour areas for both specific and non-specific antibodies. The ascites was checked to determine whether the antibodies were complexed out and, using SDS gels, this was found to be the case Using cell free effusions from benign and malignant tumours, a significant difference was found in their ability to promote clonogenic growth of normal cells in soft agar. Preliminary conclusions from this study suggests that the growth factor from mesothelial cells is unstable and not specific to malignancy but that the transforming activity of malignant effusions is greater than that of benign, that it could be a diagnostic feature and that it may contribute in vivo to the spread of ovarian cancer. In answer to Drs Hill, Leake This 3 day meeting was wide ranging in topics and vigorous discussions were pursued following the presentations. In spite of considerable optimism, however, about new methods of diagnosing and monitoring of the disease and the success of properly administered chemotherapy for some patient sub-groups, the concensus of the meeting was that it was the skill and interest of the surgeon which had the greatest influence on patient survival and that the benefits of advances in these former areas would not be realised without more widespread practice of cytoreductive surgery.
